Assessment of a multistrain probiotic (symprove) as a dietary supplement in patients with inflammatory bowel disease who are in 'clinical' remission

Kings College Hospital NHS Foundation Trust (UK)0 个研究点目标入组 160 人开始时间: 2010年8月5日最近更新: 2017年5月8日

适应症

试验速览

暂无简介。

•1. Patients aged 18 - 65 years, either sex
•2. Minimum 6 months history of inflammatory bowel disease
•3. Confirmed both endoscopically and histologically
•4. Three months of 'stable clinical remission' - including no change in treatment during the preceding 3 months

•1. Aged less than 16 years and greater than 65 years
•2. Severe disease or current disease flare
•3. Current use of biological or immunosupressive treatments (including infliximab, adalimumab, methotrexate, azathioprine, 6-mercaptopurine, cyclosporin). Patients who are taking azathioprine or 6-mercaptopurine who have been stable on treatment for a minimum of 12 weeks without major side effects or adverse events will not be excluded.
•4. Previous complicated bowel resections or multiple bowel resections
•5. Pregnancy or actively seeking pregnancy
•6. History of intolerance or allergy to probiotics
•7. Significant comorbid conditions (to be judged by the research doctor at assessment)
•8. Significant psychiatric comorbidity (to be judged by the research doctor at assessment)
•9. Current drug or alcohol dependence syndrome

发起方

Kings College Hospital NHS Foundation Trust (UK)